GENB vs RLAY
GENB: Generate Biomedicines is an AI-powered biotechnology company focused on creating a new generation of programmable protein therapeutics. RLAY: Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases.
Side-by-side fundamentals
| Metric | GENB | RLAY | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $16.12 | $19.44 | |
| Market cap as of 2026-08-24 | $2.1B | $4.3B | |
| Net margin as of 2026-08-24 | -637.0% | -2047.2% | GENB higher |
| Operating margin as of 2026-08-24 | -737.0% | -2222.7% | GENB higher |
| ROE as of 2026-08-24 | -103.7% | -42.3% | RLAY higher |
| ROA as of 2026-08-24 | -61.5% | -38.7% | RLAY higher |
| Debt / equity as of 2026-08-24 | 0.01 | 0.00 | RLAY lower |
| Revenue growth (YoY) as of 2026-08-24 | -37.7% | +23.9% | RLAY higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +123.2% | |
| Beta as of 2026-08-24 | 0.54 | 1.70 | |
| 1-year return as of 2026-08-21 close | n/a | +470.1% |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.